Short Courses and Special Courses

Molecular Diagnostic and Genomic Applications in Cancer: A Primer for the Pathologists

Tuesday, March 20, 2018 - 8:00 am - 5:00 pm

Session Credits:

7.25 CME and 5 SAMs

Course Directors:

George J. Netto MD, The University of Alabama at Birmingham, UAB Medicine, Birmingham, AL
Karen Kaul, MD, PhD, North Shore University Health System, Evanston, IL

Course Description

The pathologist is now expected to play a central role in the management of cancer patients in the era of personalized oncology. Efforts to develop residency curricula that will address the educational needs in molecular and genomic pathology for pathologists in training are underway by academic institutions and professional organizations. Similar educational needs are evident among practicing pathologists in the community and academic centers, pathology residents and fellows. In its 4th edition; this special course is offered by experts in the field of genomic diagnostics keeping the above educational needs of the practicing pathologists and pathology trainees in mind. A general overview of next generation sequencing and practical challenges to implementation of latest technologic platforms in molecular diagnostic laboratories is follow by a detailed organ base discussion of the latest applications of genomic diagnostics in oncologic pathology. A primer on immunotherapy and immunogenomics advances is also included. The course content is annually updated to reflect the latest practice guidelines and standard of care in this most rapidly changing field. Furthermore, the lectures list is adjusted annually with new topics added to reflect the advances in areas where the impact of genomics is reaching and to satisfy repeat attendants interest.

8:00 AM Introduction

George J. Netto MD, The University of Alabama at Birmingham, UAB Medicine, Birmingham, AL

8:05 AM Current Next Generation Sequencing Technology: A Primer to the Anatomic Pathologist

Wayne W. Grody, MD, PhD, University of California, Los Angeles School of Medicine, Los Angeles, CA

Upon completion of this activity, learners will be better able to:

  • Discuss the overall principles of massively parallel sequencing (next generation sequencing) technologies.
  • Illustrate practical examples of NGS based clinical diagnostics and how it will impact daily practice of pathology.
8:45 AM Next-Gen Surgical Pathology: New opportunities and Challenges

Karen Kaul, MD, PhD, North Shore University Health System, Evanston, IL

Upon completion of this activity, learners will be better able to:

  • Discuss how the evolving understanding of molecular events underlying cancer development is making molecular characterization of tumors a necessity for diagnosis and prognostication in the practice of the pathologist.
  • Present an overview of the evolution of molecular testing from single gene or mutation analysis to multiplex capabilities including next generation sequencing.
  • Discuss the challenges and opportunities associated with the incorporation of these tools into the daily practice of the pathologist.
9:10 AM Molecular Testing of Solid Tumors: Anatomic Pathologist in Charge of Pre-analytics

Anna Yemelyanova, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Upon completion of this activity, learners will be better able to:

  • Identify specimen requirements for molecular testing of solid tumors.
  • Provide criteria for the specimen selection for molecular testing.
  • Highlight challenges related to use of archival material and formalin fixed paraffin embedded tissue.
  • Evaluate algorithms for specimen triage and optimal sample utilization.
9:35 AM Molecular Advances in Gynecologic Pathology: An update for the Anatomic Pathologist

Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY<

Upon completion of this activity, learners will be better able to:

  • Discuss the genomic landscape and molecular based classifications of endometrial and ovarian cancers.
  • Review the clinically relevant genetic alterations in other gynecologic malignancies.
  • Discuss the role of genetic testing in guiding management in gynecologic malignancies.
10:00 AM Break/Poster Session

 

10:30 AM Molecular Markers for Targeted Lung Cancer Therapy

John Iafrate, MD, PhD, Massachusetts General Hospital, Boston, MA

Upon completion of this activity, learners will be better able to:

  • State the current genetic landscape of lung tumors.
  • Identify the role of genetic testing in guiding targeted therapies in lung cancer.
  • Appreciate the importance of advanced technologies in the future of pathologic assessment of tumors.
11:10 AM Molecular Testing of Bone and Soft Tissue Tumors

Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE

Upon completion of this activity, learners will be better able to:

  • Review technical processing considerations and test selection for NGS, RT-PCR, FISH, and cytogenetic analyses as they pertain to evaluating mesenchymal neoplasms.
  • Describe the advantages and limitations of genetic approaches commonly used in the classification of mesenchymal neoplasms.
  • Recognize the diagnostic, prognostic, and therapeutic value of molecular markers in mesenchymal neoplasms.
11:10 AM Role of the Pathologist in Guiding Immuno-oncological Therapies

Scott Rodig, MD, PhD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Upon completion of this activity, learners will be better able to:

  • Review clinical outcomes in solid tumors and hematological malignancies to novel immunotherapies.
  • Discuss histopathological and genetic correlates of clinical response to immunotherapy.
  • Review current applications of diagnostic pathological methods to guide immunotherapy.
  • Describe development and implementation of novel diagnostic methods to guide immunotherapy.
12:00 PM Lunch Break

 

1:00 PM Molecular Testing in the Management of Patients with Breast Cancer: Current Status and Future Directions

Stuart J. Schnitt, MD, Brigham and Women's Hospital, Boston, MA

Upon completion of this activity, learners will be better able to:

  • Explain the molecular classification of breast cancer and its clinical implications.
  • Review the uses and limitations of currently available molecular prognostic tests for patients with breast cancer.
  • Describe the emerging role of exome /whole genome sequencing in the management of patients with breast cancer.
1:40 PM Molecular Diagnostics of Head and Neck Tumors

Justin Bishop, MD, University of Texas Southwestern, Dallas, TX

Upon completion of this activity, learners will be better able to:

  • Review HPV-related Oropharyngeal SCC entities (location, prognosis, histology)
  • Discuss HPV testing strategies in the Head & Neck tumors
  • Discuss newly described tumor-defining translocations in salivary gland tumors
2:10 PM Colorectal Cancer: Update on Molecular Testing and Practice Guidelines

Antonia R. Sepulveda, MD, PhD, Columbia University, New York, NY

Upon completion of this activity, learners will be better able to:

  • Discuss MSI and DNA mismatch repair IHC testing and germline DNA mismatch repair gene sequencing role in the diagnosis and management of patients with HNPCC.
  • Discuss microsatellite instability as predictive biomarker for immunotherapy blockade and as prognostic biomarker in colorectal cancer (CRC).
  • Discuss RAS mutations use in predicting response to anti-EGFR therapies for patients with metastatic CRC.
  • Describe the role of BRAF testing in CRC.
  • Describe the emerging role of liquid biopsy in the management of CRC.
  • Describe the emerging role of exome/whole genome sequencing in the management of CRC.
3:00 PM Break/Poster Session

 

3:30 PM GIST and Melanoma: The KIT Connection and So Much More

Alexander Lazar, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX

Upon completion of this activity, learners will be better able to:

  • Illustrate the techniques and results of molecular testing for gastrointestinal stromal tumor (GIST) and melanoma.
  • Recognize the association between histologic and molecular features in GIST and melanoma.
  • Interpret the emerging role of molecular diagnostics in patient management for GIST and melanoma.
4:05 PM Molecular Diagnostics of CNS Tumors

Arie Perry, MD, University of California, San Francisco School of Medicine, San Francisco, CA

Upon completion of this activity, learners will be better able to:

  • Review the most common molecular alterations in CNS tumors
  • Recognize the association between histologic and molecular features in CNS tumors.
  • Interpret the emerging role of molecular diagnostics in patient management for CNS tumors
4:35 PM Emerging Immunologic Biomarkers: PD-L1 and Beyond

Janis Taube, MD, PhD, Johns Hopkins University, Baltimore, MD

Upon completion of this activity, learners will be better able to:

  • Introduce mechanisms of PD-L1 expression
  • Discuss the association of immunoarchitectural features of the tumor microenvironment and relationship to response with anti-PD-1/PD-L1 checkpoint blockade
  • Compare available assays for PD-L1 detection in surgical pathology specimens
  • Discuss the relationship of PD-L1 expression to other predictive biomarkers such as mutational load
5:00PM Question Period and Concluding Remarks

Karen Kaul, MD, PhD, North Shore University Health System, Evanston, IL


Continuing Medical Education and Maintenance of Certification

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Learners must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 5 SAM credit hours.

 

Return to 2018 Annual Meeting Special Course Page

Meetings

view more